Aptose Biosciences - Chart Of The Day
Summary
- 100% technical buy signals.
- 13 new highs and up 49.56%in the last month.
- 347.09% gain in the last year.
The Barchart Chart of the Day belongs to the clinical biomedical company Aptose Biosciences (APTO). I found the stock by sorting Barchart's Top100 Stocks list first by the most frequent number of new highs in the last month, then I used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 11/7 the stock gained 257.29%.
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes, and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada.
(Click on image to enlarge)
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can, therefore, change during the day as the market fluctuates. The indicator numbers shown below, therefore, may not match what you see live on the Barchart.com website when you read this report.
Barchart technical indicators:
- 100% technical buy signals
- 260.09+ Weighted Alpha
- 347.09% gain in the last year
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 13 new highs and up 49.56% in the last month
- Relative Strength Index 80.34%
- Technical support level at 7.60
- Recently traded at 8.25 with a 50 day moving average of 5.67
Fundamental factors:
- Market Cap $601 million
- Wall Street analysts give their projections on earnings and predict that earnings will grow 24.40% this year and an additional 22.20% next year
- 4 analysts give the stock 3 string buy and 1 buy recommendation
- 3,511 investors are monitoring the stock on Seeking Alpha
Disclosure: None.